Compare Amgen, Inc. (AMGN) vs eBay Inc (EBAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs eBay Inc — how do they compare? Amgen, Inc. trades at $415.99 (market cap $224.14B), while eBay Inc trades at $102.47 (market cap $47.17B). The key difference: Amgen, Inc. is far larger — about 4.8× eBay Inc's market cap, and Amgen, Inc. pays the higher dividend (2.43%). Which is the better fit depends on your goals.
| AMGN | EBAY | |
|---|---|---|
Market Cap | $224.14B | $47.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $417.20 | $118.96 |
52-Week Low | $271.18 | $79.41 |
Enterprise Value | $267.45B | $51.00B |
Dividend Yield | 2.43% | 1.17% |
Volume | — | 5,186,418 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
EBAY stock trades at $102.62, down 4.73% on news that GameStop may abandon its $56 billion takeover bid in favor of a partnership. The stock exhibits a bearish technical signal with key support at $104, while fundamentals show strong profitability with an 18.57% net income margin and consistent earnings beats in recent quarters. Revenue growth is projected to reach $12.0 billion in 2026, though cash flow turned negative in 2025.
The outlook is mixed: analyst consensus targets $119.31 with 46% buy ratings, but near-term sentiment is pressured by takeover uncertainty. Risks include competitive threats in e-commerce and reliance on focus categories. Upside hinges on execution of live shopping initiatives and potential partnership benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About eBay Inc
eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →
